Targeting the p53 tumour suppressor is appealing as p53 is widely dysregulated, p53-derived peptides are more abundantly presented by MHC-I on cancer cells and therefore p53-targeting TCRm could have broad therapeutic applications [9]. This evidence concerns the gene TP53 and cancer.